Crohn’s Disease News and Research

RSS

GSK Returns Vercirnon Rights To Chemocentryx After Phase III Flop

...

19 Sep 2013

GSK Returns Vercirnon Rights To Chemocentryx After Phase III Flop

...

18 Sep 2013

RedHill Biopharma to initiate phase III trial of RHB 104 in Crohn's disease patients

UCF College of Medicine professor Dr. Saleh Naser soon will participate in a clinical trial to test whether a new antibiotic therapy acquired by RedHill Biopharma can be used to treat Crohn's disease patients.

18 Sep 2013

Model including dozens of mutations helps clarify genetic factors involved in Crohn's disease

A statistical model accounting for dozens of different genes in combination-and the interactions between them-is an important step forward in understanding the genetic factors affecting the risk of Crohn's disease (CD), reports a study in Inflammatory Bowel Diseases, official journal of the Crohn's & Colitis Foundation of America (CCFA). The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

26 Aug 2013

Understanding genetic factors that affect Crohn's disease risk

A statistical model accounting for dozens of different genes in combination—and the interactions between them—is an important step forward in understanding the genetic factors affecting the risk of Crohn's disease, reports a study in Inflammatory Bowel Diseases, official journal of the Crohn's & Colitis Foundation of America.

23 Aug 2013

Takeda announces publication of data from two vedolizumab Phase 3 studies for ulcerative colitis and Crohn’s disease

Takeda Pharmaceutical Company Limited today announced that results from two Phase 3 studies evaluating vedolizumab, an investigational humanized monoclonal antibody, for the treatment of adults with moderately to severely active ulcerative colitis and Crohn’s disease, were published in the August 22, 2013 issue of the New England Journal of Medicine.

22 Aug 2013

New antibody drug shows positive results for treating Crohn's disease, ulcerative colitis

Vedolizumab, a new intravenous antibody medication, has shown positive results for treating both Crohn's disease and ulcerative colitis, according to researchers at the University of California San Diego, School of Medicine. The findings, published in two papers, will appear in the August 22 issue of the New England Journal of Medicine (NEJM).

22 Aug 2013

Probiotic does not prevent clinical relapse in patients with Crohn's disease

Despite previous data showing beneficial effects, the probiotic Saccharomuces boulardii (S. boulardii) does not prevent clinical relapse in patients with Crohn's disease, according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.

16 Aug 2013

First clinical study for development of SGX203 to treat pediatric Crohn's disease

Soligenix, Inc. (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that it has enrolled and treated all patients in the Phase 1 Study BDP-PCD-01; the first clinical study for development of SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) for the treatment of pediatric Crohn's disease.

1 Jul 2013

Study: Children with Crohn's disease have enterovirus in their intestines

A new study reveals that all children with Crohn's disease that were examined had a commonly occurring virus - an enterovirus - in their intestines. This link has previously not been shown for this chronic inflammatory intestinal disorder. The findings are being published today in the latest issue of the international journal Clinical and Translational Gastroenterology.

28 Jun 2013

Research highlights benefits of vitamin D, diet changes in patients with Crohn's disease

Research presented at Digestive Disease Week explores new methods for managing digestive health through diet and lifestyle.

20 May 2013

Soligenix starts first clinical study for development of SGX203 for pediatric Crohn's disease

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that it has initiated the first clinical study for development of SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) for the treatment of pediatric Crohn's disease.

15 May 2013

Ulcerative colitis and Crohn’s disease treatments: an interview with Dr Parikh, vice president, general medicine, Takeda

Ulcerative colitis (UC) and Crohn’s disease (CD) are both relapsing and remitting chronic diseases of bowel inflammation. By that I mean they flare and physicians try to get the flare under control and try to induce remission. However, despite a number of treatments available, they tend to relapse.

From Takeda 3 Apr 2013

Investigational treatment for ulcerative colitis (UC) and Crohn’s disease (CD) has Marketing Authorisation Application submitted

Takeda Pharmaceutical Company Limited (“Takeda”) today announced that a Marketing Authorisation Application (MAA) has been submitted to The European Medicines Agency (EMA) for vedolizumab, an investigational, gut-selective humanized monoclonal antibody for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD), the two most common types of inflammatory bowel disease (IBD).

8 Mar 2013

No increased risk for inflammatory bowel disease with isotretinoin

Researchers report no link between isotretinoin use for the treatment of acne and increased risk for inflammatory bowel disease in women of reproductive age.

1 Mar 2013

IL-13 protein could be the key to development of fibrosis in Crohn's disease

New research has shown that a protein, known as IL-13, could be the key to the development of fibrosis in Crohn's disease. This breakthrough could help to advance new medicines to treat people suffering with the disease.

30 Jan 2013

Refined mapping finds over 200 Crohn’s Disease genes

Researchers have used a genetic mapping technique to identify more than 200 genes associated with Crohn’s Disease, making it the most well-characterized disorder to date.

31 Dec 2012

UCL scientists discover more than 200 gene locations for Crohn's disease

More than two hundred gene locations have now been identified for the chronic bowel condition Crohn's Disease, in a study that analysed the entire human genome.

13 Dec 2012

UCB directs national effort to educate public about Crohn's disease

In recognition of Crohn's and Colitis Awareness Week (December 1-7), UCB, Inc. is directing a national effort to educate the public about Crohn's disease and inspire those living with the condition to speak out about it.

1 Dec 2012

Soligenix receives FDA Fast Track designation for SGX203 to treat pediatric Crohn's disease

Soligenix, Inc., a development stage biopharmaceutical company, announced today that its program for development of SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) for the induction treatment of mild-to-moderate pediatric Crohn's disease has received "Fast Track" designation from the U.S. Food and Drug Administration (FDA).

8 Nov 2012

Crohn’s Disease News and Research

GSK Returns Vercirnon Rights To Chemocentryx After Phase III Flop

GSK Returns Vercirnon Rights To Chemocentryx After Phase III Flop

RedHill Biopharma to initiate phase III trial of RHB 104 in Crohn's disease patients

Model including dozens of mutations helps clarify genetic factors involved in Crohn's disease

Understanding genetic factors that affect Crohn's disease risk

Takeda announces publication of data from two vedolizumab Phase 3 studies for ulcerative colitis and Crohn’s disease

New antibody drug shows positive results for treating Crohn's disease, ulcerative colitis

Probiotic does not prevent clinical relapse in patients with Crohn's disease

First clinical study for development of SGX203 to treat pediatric Crohn's disease

Study: Children with Crohn's disease have enterovirus in their intestines

Research highlights benefits of vitamin D, diet changes in patients with Crohn's disease

Soligenix starts first clinical study for development of SGX203 for pediatric Crohn's disease

Ulcerative colitis and Crohn’s disease treatments: an interview with Dr Parikh, vice president, general medicine, Takeda

Investigational treatment for ulcerative colitis (UC) and Crohn’s disease (CD) has Marketing Authorisation Application submitted

No increased risk for inflammatory bowel disease with isotretinoin

IL-13 protein could be the key to development of fibrosis in Crohn's disease

Refined mapping finds over 200 Crohn’s Disease genes

UCL scientists discover more than 200 gene locations for Crohn's disease

UCB directs national effort to educate public about Crohn's disease

Soligenix receives FDA Fast Track designation for SGX203 to treat pediatric Crohn's disease

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News